Figitumumab, Sutent miss in Phase IIIs
Pfizer Inc. (NYSE:PFE) announced it discontinued a Phase III trial of figitumumab to treat non-small cell lung cancer (NSCLC) and said that Sutent sunitinib missed the primary endpoint in two Phase III trials to treat breast cancer. Pfizer ended the open-label ADVIGO 1018 trial of figitumumab after a DSMC said the human mAb targeting insulin-like growth factor-1 (IGF-1) receptor plus Tarceva erlotinib would be unlikely to meet the primary endpoint of significantly improving overall survival (OS) vs. Tarceva alone in patients with refractory advanced non-adenocarcinoma NSCLC. Last year, the pharma ended the Phase III ADVIGO 1016 trial of figitumumab for advanced non-adenocarcinoma NSCLC after a DSMC said the mAb plus paclitaxel and carboplatin would be unlikely to meet the primary endpoint of improving OS vs. paclitaxel and carboplatin. Figitumumab also is in the clinic for other cancers, including prostate and breast cancer. Tarceva is marketed by OSI Pharmaceuticals Inc. (NASDAQ:OSIP), Roche (SIX:ROG; OTCQX:RHHBY) and Roche's Genentech Inc. unit. ...